MEDIVIR AB - INTERIM REPORT JANUARY

/PRNewswire/ -- Preparations for the planned phase 2b study continue according to plan after the completed Type C meeting with the FDA, strengthened by the...

Related Keywords

France ,Perthes ,Champagne Ardenne ,Stockholm ,Sweden ,San Francisco ,California ,United States ,Magnus Christensen ,Anders Hallberg ,Jens Lindberg ,Stefan Bengtsson , ,January Tango Therapeutics ,Hallberg Management ,Healthinvest Partners ,Rare Pediatric Disease Designation ,Orphan Drug Designation ,Interim Report January ,Objective Response Rate ,Tango Therapeutics ,Perthes Disease ,Medivir ,